fbpx
Sign up now!
Don't show this again
Sweepstakes Rules
Download the report!Continue to Site >
or wait 7 secs

Thank you for confirming your subscription!

(And remember, if ever you want to change your email preferences or unsubscribe, just click on the links at the bottom of any email.)

We’re glad you’re enjoying Pig Health Today.
Access is free but you’ll need to register to view more content.
Already registered? Sign In
Tap to download the app
X
Share
X

REPORTS

Collect articles and features into your own report to read later, print or share with others

Create a New Report

Favorites

Read Later

Create a new report

Report title (required) Brief description (optional)
CREATE
X
NEXT
PORK POULTRY
follow us


You must be logged in to edit your profile.

Favorites Read Later My Reports PHT Special Reports
Pig Health Today is equipped with some amazing (and free) tools for organizing and sharing content, as well as creating your own magazines and special reports. To access them, please register today.
Sponsored by Zoetis

Pig Health Today | Sponsored by Zoetis

.

Suvaxyn® PRRS MLV protects against highly pathogenic PRRSV-1 field strain

15 seconds

  • Pigs vaccinated at 1 day of age with Suvaxyn® PRRS MLV had less viremia and nasal shedding than unvaccinated pigs following challenge on day 28 with a virulent field strain of porcine reproductive and respiratory syndrome virus (PRRSV-1).
  • Study results confirm ability of Suvaxyn PRRS MLV to provide protection prior to weaning when given to day-old piglets in the presence of maternal passive immunity.
  • Reducing viremia and shedding in weaned piglets is critical to curbing the spread of virulent PRRSV-1 field strains and associated mortalities and performance losses.

 

A new study shows that a modified-live virus (MLV) vaccine for porcine reproductive and respiratory syndrome virus (PRRSV) provides protection against the highly pathogenic European field isolate AUT15-331 (PRRSV-1, subtype 1) — with a single dose given to day-old piglets enough to significantly reduce viremia and nasal shedding compared to unvaccinated controls.

PRRSV causes reproductive disease in sows and is also associated with respiratory problems, secondary infections and reduced performance in growers and finishers. Mortality varies but can be extremely high in some cases.2,3 New, highly pathogenic strains of the virus such as AUT15-33 present a significant threat to the swine industry, with the effects of PRRSV already costing European producers approximately €1.5 billion per year.4 Researchers from Zoetis and the University of Veterinary Medicine, Vienna, therefore conducted a study to evaluate the ability of Suvaxyn® PRRS MLV to reduce viremia and viral shedding following experimental infection with PRRSV-1 AUT15-33.

Study design and results

In the study, 21 piglets were intramuscularly vaccinated with Suvaxyn PRRS MLV at 1 day of age according to label instructions, while 20 piglets were sham-treated and served as unvaccinated controls. At 28 days of age, all piglets were challenged intranasally with PRRSV-1 AUT15-33. After weaning, the vaccinated and unvaccinated pigs were commingled and observed for 2 weeks. Serum, nasal and oral swabs were collected every 2 to 3 days and analyzed by real-time quantitative polymerase chain reaction.

Serum and nasal swabs from the vaccinated piglets had significantly (p < 0.05) lower loads of PRRSV RNA than those from unvaccinated piglets on most sampling days (Figures 1 and 2). All of the unvaccinated piglets were viremic and had virus in nasal swabs, whereas only 71.4% of the vaccinated animals were viremic and 38.1% shed virus.

In addition, the percentage of days with viremia in the group of vaccinated pigs was 19.6% compared to 55.1% for the unvaccinated animals.

 

Click to enlarge

 

Reduced viremia and shedding cuts risk to herds

“Reducing viremia and shedding through vaccination is critical to curbing the spread of PRRSV-1 field strains among weaned piglets and limiting related losses,” explained Marta Cabana, DVM, PhD, a research and development scientist at Zoetis and principal investigator of the study.

“This work confirms the ability of Suvaxyn PRRS MLV to provide protection against virulent PRRSV-1 field strains, including AUT15-33, by weaning when administered at 1 day of age,” she added, noting that Suvaxyn PRRS MLV is the only commercial PRRSV-1 vaccine in the EU authorized for use in day-old pigs.

“Being able to vaccinate on day 1 helps close the gap in immunity between the loss of maternal antibodies around 3 to 4 weeks of age and the onset of vaccine immunity, ensuring pigs are protected from before weaning through slaughter.”5

 

 

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted.

 

1 Kreuzmann H, et al. Vaccination of neonatal piglets against PRRSV significantly reduces viremia and viral shedding. Poster, ESPHM 2020+2021.
2 Montaner-Tarbes S, Del Portillo HA, Montoya M, Fraile L. Key gaps in the knowledge of the porcine respiratory reproductive syndrome virus (PRRSV). Frontiers Vet Sci. 2019;6:38.
3 Sinn LJ, et al. Emergence of a virulent porcine reproductive and respiratory syndrome virus (PRRSV) 1 strain in Lower Austria. Porcine Health Manag. 2016;2:28. doi:10.1186/s40813-016-0044-z.
4 De Paz X. PRRS cost for the European swine industry. Pig333.com. 2015 Aug. Located at https://www.pig333.com/articles/prrs-cost-for-the-european-swine-industry_10069/.
5 Balasch M, Fort M, Taylor LP, Calvert JG. Vaccination of 1-day-old pigs with a porcine reproductive and respiratory syndrome virus (PRRSV) modified live attenuated virus vaccine is able to overcome maternal immunity. Porcine Health Manag. 2018 Nov 15;4:25. Located at https://pubmed.ncbi.nlm.nih.gov/30459958/.

 

 

DISCOVERIES
Discoveries is a series of research news reports written by the editors of Pig Health Today® on behalf of the Global Pork Business of Zoetis.

 

©2021 Zoetis Services LLC. All rights reserved.      October 2021      MM-16832

Share It
Pigs vaccinated with Suvaxyn®️ PRRS MLV at 1 day of age had less viremia and nasal shedding than unvaccinated pigs when challenged with a virulent European field strain of porcine reproductive and respiratory syndrome virus (PRRSV-1), a new study shows.

Click an icon to share this information with your industry contacts.



Posted on October 20, 2021

tags: , ,
RELATED NEWS



You must be logged in to edit your profile.

Share It
Looking at individual “pieces of the puzzle” means farm owners can evaluate the pros and cons of Mycoplasma elimination programs and come to a practical solution, says veterinarian David A. Baumert.

Click an icon to share this information with your industry contacts.
Google Translate is provided on this website as a reference tool. However, Poultry Health Today and its sponsor and affiliates do not guarantee in any way the accuracy of the translated content and are not responsible for any event resulting from the use of the translation provided by Google. By choosing a language other than English from the Google Translate menu, the user agrees to withhold all liability and/or damage that may occur to the user by depending on or using the translation by Google.